Every 8-K that Heartflow, Inc. (HTFL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow HTFL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HTFL filings page.
Heartflow, Inc. reported strong growth for the quarter ended June 30, 2026. Total revenue was $64.1 million, a 48% increase year-over-year, driven mainly by higher U.S. case volumes in both FFRCT and Plaque. U.S. revenue reached $59.6 million, up 51%, while international and other revenue was $4.5 million, up 12%.
GAAP gross profit rose to $53.2 million with gross margin expanding to 83.0% from 75.5%, helped by AI-driven productivity and growing Plaque volumes. Operating expenses increased to $71.1 million as the company invested in sales, technology and clinical research, resulting in a GAAP net loss of $15.7 million and Adjusted EBITDA of ($6.7) million, both better than the prior-year quarter on a non-GAAP/EBITDA basis. Non-GAAP net loss improved to $5.8 million. Cash, cash equivalents and investments totaled $246.8 million as of June 30, 2026. Management stated that it raised full-year 2026 guidance and highlighted record gross margin and improving operating leverage.
Heartflow, Inc. held its 2026 Annual Meeting of Stockholders on June 16, 2026, where shareholders voted on board elections and auditor ratification. Two Class I directors, Julie A. Cullivan and John C.M. Farquhar, were elected to three-year terms ending at the 2029 annual meeting.
Shareholders cast 51,986,481 votes for and 6,046,730 withheld for Cullivan, and 52,277,825 for and 5,755,386 withheld for Farquhar, with 11,550,151 broker non-votes on each nominee. Stockholders also approved PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026, with 68,735,861 votes for, 717,413 against, and 130,088 abstentions.
Heartflow, Inc. reported strong first quarter 2026 results, with total revenue of $52.6 million, a 41% increase year-over-year, and raised its full year 2026 guidance. U.S. revenue was $48.3 million, up 42%, while international and other revenue reached $4.3 million, up 34%.
GAAP gross profit grew to $42.2 million and gross margin improved to 80.2% from 75.1%, helped by higher case volumes and AI-driven productivity gains. Total operating expenses increased to $71.7 million, including a $7.5 million non-cash impairment tied to optimizing facilities and moving the headquarters to San Francisco.
Net loss narrowed to $27.4 million, or $0.32 per share, from $32.3 million, while non-GAAP net loss improved to $13.3 million, or $0.16 per share. Adjusted EBITDA was a loss of $14.0 million. Heartflow ended March 31, 2026 with $254.9 million in cash, cash equivalents and investments, supporting continued investment in sales, technology, and clinical research.
Heartflow, Inc. reported strong growth for the fourth quarter and full year 2025 while remaining unprofitable. Q4 revenue was $49.1 million, up 40% year-over-year, and full-year revenue reached $176.0 million, also up 40%, driven mainly by higher U.S. FFRCT volume.
Q4 gross margin improved to 79.5%, with full-year gross margin at 76.8%, reflecting AI-driven productivity gains. However, full-year operating expenses of $199.3 million (113% of revenue) led to a GAAP net loss of $116.8 million, or ($3.17) per share.
On a non-GAAP basis, full-year net loss narrowed to $59.9 million, and Adjusted EBITDA was ($44.7) million. Heartflow ended 2025 with $280.2 million in cash, cash equivalents and investments, providing a substantial liquidity cushion to support continued investment and growth initiatives.
Heartflow, Inc. furnished an investor presentation in connection with an upcoming investor conference. The company posted the presentation on its website and attached it as Exhibit 99.1 to this report. The materials are provided under Regulation FD, and the company states that the information is being furnished, not filed, meaning it is not automatically subject to certain Exchange Act liabilities or incorporated into other securities filings unless specifically referenced.
HeartFlow, Inc. filed an 8-K announcing it has furnished a press release detailing its financial results for the quarter ended September 30, 2025. The release is attached as Exhibit 99.1 and provides the company’s Q3 2025 performance update.
The information under Item 2.02 and Item 9.01 is furnished, not filed, under the Exchange Act, meaning it is not subject to Section 18 liability and is not incorporated by reference unless specifically stated. The filing confirms Nasdaq-listed ticker HTFL and Emerging Growth Company status.
Heartflow, Inc. released preliminary, unaudited results for the three months ended June 30, 2025, in connection with an investor presentation at a healthcare conference. The company expects revenue of approximately $43.4 million, a gross margin of about 75.5%, and operating expenses near $46.5 million.
Heartflow also reports cash and cash equivalents of roughly $80.2 million as of June 30, 2025. This cash figure excludes the estimated $333.0 million of net proceeds from its August 11, 2025 initial public offering and the repayment of amounts outstanding under a credit agreement, including $114.1 million of principal as of June 30, 2025 plus accrued interest and fees.
The company notes that these figures are preliminary and unaudited and may change when it files its Form 10-Q for the quarter ended June 30, 2025.
Heartflow, Inc. reported that on August 22, 2025 it prepaid in full all outstanding obligations under its Credit Agreement with Hayfin Services LLP, then terminated the facility. The prepayment covered an aggregate principal amount of $60.1 million plus $1.0 million of accrued interest. The company states that it did not incur any exit or prepayment fees in connection with closing out this debt arrangement.
The Credit Agreement, originally dated June 14, 2024 and amended January 24, 2025, was a material financing arrangement for the company. Heartflow refers investors to the liquidity and capital resources section of its prior Form S-1 registration statement for a fuller description of the original terms.